ODTX
Odyssey Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$19.24
−2.99%Oct 20, 2026, 11:00 UTC
Odyssey Therapeutics, Inc. presented completed Phase 2a induction results for OD-001, reporting a favorable tolerability profile and oral administration in inflammatory bowel disease.
Source:Oct 6, 2026, 12:00 UTC
Odyssey Therapeutics announced that additional results from the OD-001 induction period of its Phase 2a trial in moderate to severe ulcerative colitis will be featured in an oral presentation at UEG Week 2026 in Barcelona, Spain, on October 17-20, 2026.
Source:Aug 6, 2026, 06:16 UTC
Evotec SE announced a strategic R&D collaboration with Odyssey Therapeutics to discover new treatments for autoimmune and inflammatory diseases using Evotec's AI-enabled discovery platform.
Source:Aug 4, 2026, 00:00 UTC
Odyssey Therapeutics reported a GAAP net loss of $52.8 million for Q2 2026, compared to a net loss of $41.2 million in Q2 2025, with cash and marketable securities of $433.1 million as of June 30, 2026.